Charlie Windri/LinkedIn
Apr 16, 2026, 02:57
Charlie Windri: CAC as the Missing Link in Lp(a) Risk
Charlie Windri, Laboratory Specialist at FHI 360, Clinical Pathologist at Laboratorium Dia Care Pasar Minggu, shared a post on LinkedIn:
“We’ve been treating Lp(a) like a yes-or-no problem.
It’s not.
Two patients can have the same high Lp(a)… but completely different actual risk.
What makes the difference?
Coronary artery calcium (CAC).
A new study shows CAC doesn’t replace Lp(a).
It translates it into action.
If you’re still unsure when to escalate therapy in primary prevention, this will change how you think.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 21:27Satish Bondala: Blood Bank and Transfusion Services – The Lifeline of Hospitals
-
Apr 15, 2026, 21:26Tareq Abadl: Understanding Thalassemia – Breaking the ‘Ordinary Anemia’ Myth
-
Apr 15, 2026, 21:24Wolfgang Miesbach: Key Message from John Semple on Platelets as Immune Cells in ITP
-
Apr 15, 2026, 21:22Manuel Gutiérrez de Ravé: Promotion to Real-World Evidence Scientist at Terumo Blood and Cell Technologies
-
Apr 15, 2026, 18:45Elias Lee: Acute PE from Subclavian VT – CT Scan Diagnosis, Radiology Interpretation, and Emergency Imaging Insights
-
Apr 15, 2026, 17:30Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation – Cardiology Insights and Heart Health
-
Apr 15, 2026, 17:01Emmanuel J Favaloro: A Practical Approach to Inherited and Acquired Coagulation Disorders
-
Apr 15, 2026, 16:55Chokri Ben Lamine: VA-ECMO vs VV-ECMO Thromboembolic Events – Key Clinical Pearls
-
Apr 15, 2026, 16:54Augustina Isioma Ikusemoro: The Most Misunderstood Cause of a Prolonged APTT in the Laboratory